SEC Tracker
Get the app

Arvinas ARVN

Arvinas announced Q3 2026 financial results and corporate update

Item 2.02 Reports results, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents, restricted cash, and marketable securities were $558.9 million as of September 30, 2026.
  2. Initiated dosing in Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC.
  3. Reaffirmed commitment to share clinical data from three Phase 1 programs in 4Q 2026 and 2027.
  4. Presented additional biomarker data from ARV-102 Phase 1 trial in Parkinson's disease.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Arvinas files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025
  2. aTYR PHARMA ATYR public float $464M, Jun 30, 2025
  3. Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
  4. Theravance Biopharma TBPH public float $449M, Jun 30, 2025
  5. Myriad Genetics MYGN public float $494M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.